An In vitro Experimental Study of the Cytotoxic and Antiproliferative Effects of Cabozantinib on Human Breast Cancer (Mcf-7) Cells

Abstract Background: Breast cancer remains one of the most frequently diagnosed malignancies and a leading cause of cancer-related mortality among women worldwide. Despite significant advances in therapeutic strategies, treatment resistance and disease recurrence continue to present major clinical challenges. Cabozantinib, a multitarget tyrosine kinase inhibitor, has demonstrated antitumor activity against several solid tumors; however, its direct cytotoxic effects on breast cancer cells require further investigation. Objective: The present study aimed to evaluate the cytotoxic and antiproliferative effects of cabozantinib against human breast cancer MCF-7 cells under in vitro conditions. Materials and Methods: MCF-7 cells were treated with increasing concentrations of cabozantinib (5–50 μM) for 24 h. Cell viability was assessed using the MTT assay, while cellular membrane integrity and cytotoxicity were evaluated through lactate dehydrogenase (LDH) leakage analysis. The half-maximal inhibitory concentration (IC 50 ) was determined from the dose–response curve. Results: Cabozantinib treatment resulted in a significant concentration-dependent reduction in MCF-7 cell viability. The IC 50 value was determined to be 11.42 μM, indicating potent growth-inhibitory activity. Furthermore, cabozantinib induced a marked increase in LDH release compared with untreated control cells, demonstrating progressive loss of membrane integrity and enhanced cytotoxicity. The concordance between MTT and LDH assay findings confirmed the antiproliferative and cytotoxic effects of cabozantinib against breast cancer cells. Conclusion: Cabozantinib exhibits significant cytotoxic and antiproliferative activity against MCF-7 human breast cancer cells. These findings support the potential application of cabozantinib as a targeted therapeutic agent for breast cancer and warrant further preclinical investigations to validate its anticancer efficacy.

Authors

Institutions

Publication Details

Journal
Annals of African Medicine
Published
2026-11-16
DOI
https://doi.org/10.4103/aam.aam_1038_26
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

An In vitro Experimental Study of the Cytotoxic and Antiproliferative Effects of Cabozantinib on Human Breast Cancer (Mcf-7) Cells

Akash Rawat, Amirtha Manoharan, Priyanka Ganapathy, Sanjana Sharma et al.
Annals of African Medicine
Breast Cancer Treatment Studies
article

An In vitro Experimental Study of the Cytotoxic and Antiproliferative Effects of Cabozantinib on Human Breast Cancer (Mcf-7) Cells

Akash Rawat, Amirtha Manoharan, Priyanka Ganapathy, Sanjana Sharma, W. M. S. Johnson, M. K. Anbumozhi
article en

Abstract

Abstract Background: Breast cancer remains one of the most frequently diagnosed malignancies and a leading cause of cancer-related mortality among women worldwide. Despite significant advances in therapeutic strategies, treatment resistance and disease recurrence continue to present major clinical challenges. Cabozantinib, a multitarget tyrosine kinase inhibitor, has demonstrated antitumor activity against several solid tumors; however, its direct cytotoxic effects on breast cancer cells require further investigation. Objective: The present study aimed to evaluate the cytotoxic and antiproliferative effects of cabozantinib against human breast cancer MCF-7 cells under in vitro conditions. Materials and Methods: MCF-7 cells were treated with increasing concentrations of cabozantinib (5–50 μM) for 24 h. Cell viability was assessed using the MTT assay, while cellular membrane integrity and cytotoxicity were evaluated through lactate dehydrogenase (LDH) leakage analysis. The half-maximal inhibitory concentration (IC 50 ) was determined from the dose–response curve. Results: Cabozantinib treatment resulted in a significant concentration-dependent reduction in MCF-7 cell viability. The IC 50 value was determined to be 11.42 μM, indicating potent growth-inhibitory activity. Furthermore, cabozantinib induced a marked increase in LDH release compared with untreated control cells, demonstrating progressive loss of membrane integrity and enhanced cytotoxicity. The concordance between MTT and LDH assay findings confirmed the antiproliferative and cytotoxic effects of cabozantinib against breast cancer cells. Conclusion: Cabozantinib exhibits significant cytotoxic and antiproliferative activity against MCF-7 human breast cancer cells. These findings support the potential application of cabozantinib as a targeted therapeutic agent for breast cancer and warrant further preclinical investigations to validate its anticancer efficacy.

Annals of African Medicine
Swami Rama Himalayan University (IN)
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon